Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Placebo Controlled, 12-week Treatment Trial in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

NCT05227508 is registered in ClinicalTrials.gov with Se-cure Pharmaceuticals Ltd. as lead sponsor.

NCT NCT05227508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05227508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Placebo Controlled, 12-week Treatment Trial in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Lead sponsor
Se-cure Pharmaceuticals Ltd.
Phase
Not applicable
Overall status
Unknown status
Start date
August 31, 2022
Completion date
June 30, 2024
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bph without urinary obstruction and other lower urinary tract symptoms (luts)